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(ii) Abstract 
 
Aims: Long non-coding RNAs (lncRNAs) play functional roles in physiology and disease, yet 
understanding of their contribution to endothelial cell (EC) function is incomplete. We identified 
lncRNAs regulated during EC differentiation and investigated the role of LINC00961 and its encoded 
micropeptide SPAAR in EC function. 
 
Methods and Results: Deep sequencing of human embryonic stem cell differentiation to ECs was 
combined with ENCODE RNA-seq data from vascular cells, identifying 278 endothelial enriched 
genes, including 6 lncRNAs. Expression of LINC00961, first annotated as a lncRNA but reassigned as 
a protein coding gene for the SPAAR micropeptide, was increased during the differentiation and was 
EC-enriched. LINC00961 transcript depletion significantly reduced EC adhesion, tube formation, 
migration, proliferation, and barrier integrity in primary ECs. Overexpression of the SPAAR open 
reading frame increased tubule formation, however overexpression of the full length transcript did not, 
despite production of SPAAR. Further, overexpression of an ATG mutant of the full length transcript 
reduced network formation, suggesting a bona fide non-coding RNA function of the transcript with 
opposing effects to SPAAR.  As the LINC00961 locus is conserved in mouse, we generated a 
LINC00961 locus knockout (KO) mouse that underwent hind limb ischaemia to investigate the 
angiogenic role of this locus in vivo. In agreement with in vitro data, KO animals had a reduced capillary 
density in the ischaemic adductor muscle after 7 days.  Finally, to characterise LINC00961 and SPAAR 
independent functions in ECs, we performed pull-downs of both molecules and identified protein 
binding partners. LINC00961 RNA binds the G-actin sequestering protein thymosin beta-4x (Tβ4) and 
Tβ4 depletion phenocopied the overexpression of the ATG mutant. SPAAR binding partners included 
the actin binding protein, SYNE1.   
 
Conclusion: The LINC00961 locus regulates EC function in vitro and in vivo.  The gene produces two 
molecules with opposing effects on angiogenesis: SPAAR and LINC00961.  
 
Words 298  
 
 
Translational Perspective (100 words): 
Treatment of ischemic conditions remains a major cardiovascular health burden. Identification of genes 
and non-coding RNAs that regulate the function of the vascular endothelium is important to understand 
and evolve potential new strategies that might enhance vascular regeneration. Here, we describe and 
dissect the functional importance of a micropeptide-encoding RNA transcript in the vascular 
endothelium, and demonstrate that both the RNA and the peptide regulate endothelial biology. 
Modulation of this axis may be a novel approach to regulate angiogenesis. 
 
Non-standard Abbreviations and Acronyms  
aa: Amino acids 
α-sma: α-smooth muscle actin 
bp: Base pairs 
DsiRNA: Dicer substrate siRNA 
EC: Endothelial cell 
ECIS: Electric cell-substrate impedance sensing assay 
ENCODE: Encyclopedia of DNA Elements 
FISH: Fluorescent in situ hybridisation 
GO: Gene Ontology 
hESC: Human embryonic stem cell  
HSVEC: Human saphenous vein endothelial cell 
HUVEC: Human umbilical vein endothelial cell 
IB4: Isolectin B4 
KD: Knock down 
KO: Knock out 
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lincRNA: Intergenic lncRNA 
lncRNA: Long non-coding RNA  
LV: Lentiviral 
MP: Day 3 mesodermal population 
ncRNA: non-coding RNA 
ORF: Open reading frame 
PCA: Principal component analysis  
SMC: Smooth muscle cell 
SPAAR: Small regulatory polypeptide of amino acid response 
Tβ4: Thymosin beta-4x 
UBC: Ubiquitin C 
WT: Wild type 
 
(iii) INTRODUCTION  
 
The endothelium is a heterogeneous organ system that regulates homeostasis of the vasculature and 
represents a permeable monolayer barrier between the vessel wall and the blood. Endothelial cells (ECs) 
regulate and adapt to shear stress, leukocyte extravasation, blood clotting, inflammation, vascular tone, 
extracellular matrix deposition, vasoconstriction/vasodilation, and angiogenesis. During angiogenesis, 
ECs become activated and undergo sprouting, proliferation, migration along a gradient of pro-
angiogenic factors (eg. VEGF, FGF, PDGF), and anastomose to form new capillaries before returning 
to their quiescent state 1. Aberrant activation however, leads to EC dysfunction that can cause systemic 
vascular pathology 1, 2. This uncontrolled activation is a significant factor contributing to coronary artery 
disease, diabetes, hypertension patients, hypercholesterolemia, lupus, and has been reported as 
increased in smokers 3, 4. 
Several groups have demonstrated the ability to differentiate ECs from human embryonic stem cells 
(hESC) 5-7. This protocol yields ECs that are relatively immature and express genes that are somewhat 
distinct from those of mature ECs from various vascular beds 8, highlighting the importance of 
understanding the molecular mechanisms controlling both general and specialised EC differentiation, 
specification, and function. These derived ECs have been extensively proven to be functional both in 
vitro, by the ability to form capillary like networks on Matrigel 7 and in vivo, by their ability to improve 
vascular density and perfusion in a murine model of hind limb ischaemia (HLI) 9. These data provide 
evidence of the benefits to hESC-derived EC for therapeutics and as a model to characterise early 
vascular development. 
Data from the human Encyclopedia of DNA Elements (ENCODE) project indicates that approximately 
93% of the genome is transcribed, with less than 2% encoding protein sequences 10. Currently, these 
non-coding RNAs (ncRNAs) are classified based on size, into long non-coding RNAs (lncRNAs) 
>200bp and small ncRNAs < 200bps. LncRNAs correspond to a heterogeneous class of genes, with 
subtypes classified based on neighbouring protein-coding genes. In particular, lincRNAs are intergenic 
lncRNAs with no overlap with protein-coding genes. While some lincRNAs regulate in cis their protein-
coding neighbours expression, a large range of trans-functions have been reported including chromatin 
remodelling, transcriptional and post-transcriptional regulation, translation control and regulation of 
protein activity 11. LncRNAs show spatio-temporal expression, and are poorly conserved between 
species 12 , however, to date only a few of the lncRNAs known to exist have been functionally 
characterised. Recent literature highlights the important functions of lncRNAs as regulators of the 
cardiovascular system 13, 14.  In the vascular endothelium, TIE1-AS1 was the first described endothelial 
specific lncRNA, involved in modulating TIE-1 expression and regulating endothelial vessel formation 
15. A comprehensive transcriptome analysis of early cardiovascular development revealed the regulation 
of several lncRNAs and led to the characterisation of ALIEN and PUNISHER 16. Recently, the hypoxia-
induced lncRNA, GATA6-AS, was shown to epigenetically regulate angiogenesis through its 
interaction with the epigenetic regulator LOXL2 17, 18. 
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The “non-coding” property of some lncRNAs has been disputed by the discovery of small open reading 
frames (ORFs) in some lncRNA transcripts, able to generate functional micropeptides 19, 20. For 
example, LINC00948 has been reclassified as a protein-coding gene, as it encodes myoregulin, which 
inhibits the calcium ATPase SERCA in muscle 21. Similarly, the micropeptide DWORF encoded by 
lncRNA NONMMUG026737 activates the SERCA pump 22. Noteworthy to this study, a conserved 
micropeptide termed small regulatory polypeptide of amino acid response (SPAAR) was recently 
shown to be encoded by the LINC00961 locus 23. SPAAR attenuates lysosomal v-ATPases interaction 
with mTORC1 under amino acid stimulation and modulates skeletal muscle regeneration following 
cardiotoxin injury 23. These studies focused on the function of the derived micropeptide, however, some 
micropeptides have been shown to be expressed from lncRNAs with previously characterised non-
coding functions24, suggesting the possibility of bi-functional loci. 
 
We identified the LINC00961/SPAAR locus as EC enriched, and sought to identify the role of this 
micropeptide-encoding gene. This led to dissection of the contribution of the LINC00961 RNA 
transcript itself and the SPAAR micropeptide on endothelial function. LINC00961 RNA was found to 
act as a bona fide lncRNA that inhibited angiogenesis and bound to the known angiogenic and actin 
binding protein thymosin beta 4-x (Tβ4). Whereas SPAAR was found to be pro-angiogenic and bound 
to another actin binding protein, SYNE1.   
 
 
(iv) METHODS 
 
Endothelial cell isolation and cell culture 
All donated tissues have been obtained under proper informed consent and the investigation conforms 
with principles in the Declaration of Helsinki. Human saphenous vein endothelial cells (HSVECs) were 
obtained by enzymatic collagenase digestion of human saphenous veins (Ethics 15/ES/0094). Human 
umbilical vein endothelial cells (HUVEC) were obtained from Lonza (Basel Switzerland). 
 
RNA-Seq of human embryonic stem cell differentiation to endothelial cells  
A previously published protocol was employed to generate endothelial cells from H9 human embryonic 
stem cells 25. RNA-Seq analysis was performed as previously described 26 with minor modifications. 
Ensembl GRCh38 was used for transcriptome annotation. Read counts for each gene were obtained 
using HTSeq 27. The differential expression was analysed using DESeq2 28. RNA-seq data are deposited 
at the Gene expression Omnibus as GSE118106. 
 
Expression data from several human endothelial and smooth muscle cell (SMC) lines was obtained 
from the Encyclopedia of DNA Element (ENCODE) Consortium. The list of analysed data and their 
abbreviated name can be found in Supplementary Table 1). Candidate filtering was done as follow: (a) 
Genes enriched in day7 EC versus hESC and non-EC day sample based on a LogFC>=1, padj<0.01, 
FPKM>=2 (b) Genes up-regulated in HSVEC versus hESC (LogFC>=1, padj<0.01, FPKM>=2) (c) 
Genes expressed in ENCODE ECs (min of 2 FPKM in 10 samples) (d) Enriched expressed in ENCODE 
ECs versus ENCODE SMCs (2 fold enrichment between the average expression in ECs and SMCs). 
 
HUVEC transfection and phenotype analysis 
All phenotypes were assessed in Human umbilical vein endothelial cells (HUVECs) at 24 hours after 
transfection with dicer substrate siRNA (dsiRNA) or infection with lentiviral constructs (details of 
reagents and protocols in Supplementary Methods). In vitro tubule network formation was assessed 
using Matrigel (Corning, USA) according to the manufacturer’s protocol. Proliferation was assessed 
using the Click-it EdU 488 Proliferation assay (Life Technologies, UK). Migration and endothelial 
barrier function assays were performed using an Electric Cell-substrate Impedance Sensing (ECIS) 
machine (Applied BioPhysics) and cell viability assessed with a FITC Annexin V Detection Kit with 
PI (BioLegend). 
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Hind limb ischaemia 
All animal experiments were performed in accordance with the Animals (Scientific Procedures) Act 
(UK) 1986 and under the auspices of UK Home Office Project and Personal Licenses held within The 
University of Edinburgh facilities. LINC00961-/- mouse line was obtained from Taconic©. Validation 
of genotype was two-fold. Ear clip samples from pups were sent to Transnetyx© for genotyping, and 
in house validation was also carried out using qRT-PCR on mRNA extracted from the kidney. Surgical 
procedures were performed under inhaled general anaesthesia (isoflurane at 5% for induction and 1-2% 
for maintenance) and with appropriate peri-operative analgesic cover (subcutaneous injection of 
buprenorphine at 0.05mg/kg). Unilateral hind limb ischaemia (HLI) was surgically induced by 
left femoral artery ligation at two points and cauterisation of this segment of artery, leaving the femoral 
vein and nerve untouched. Mice were maintained for 7 days after surgery. Male LINC00961-/- and wild 
type (WT) littermates on the C57Bl/b6NTAC were studied at 11 weeks of age. Animals were euthanised 
with pentobarbital (160mg/kg) given by intraperitoneal injection. Tissues were perfusion fixed with 
PBS at 6ml/min with a micro pump and then with 4% paraformaldehyde at 6ml/min.  
 
Pull-down 
LINC00961 RNA pull-down was carried out with 50 pmol biotinylated lncRNA, obtained using the 
T7 RiboMAX Express Large Scale RNA Production System (Promega, UK). The biotinylated lncRNA 
was incubated with streptavidin magnetic beads and 20 µg of HUVECs protein lysate, using the Pierce 
Mag RNA Protein Pull-down kit (Thermo Scientific). For the SPAAR pull-down HUVECs expressing 
either LV-Null, LV-SPAAR untagged or LV-SPAAR- HA tagged were cultured in EGM-2 media. 
Immunoprecipitation with either anti-IgG or anti- HA antibody was performed in two replicates. 
SPAAR binding partners were defined as proteins detected in the two pull-down replicates and with a 
2-fold enrichment compared to the IgG pull-down controls or pull-down in cells not overexpressing 
HA-tagged SPAAR. Keratin contaminants and unknown proteins were removed from the final 
candidate list. 
 
Statistical analysis 
Statistical analysis was performed as described in the figure legends using GraphPad Prism version 5.0. 
Data are expressed as mean ± SEM. Comparisons between 2 groups were analysed using 2-tailed 
unpaired Student’s t-tests. Comparisons between more than 2 groups were analysed using One-way 
ANOVA. For qRT-PCR analysis, graphs display the expression relative to the housekeeping gene based 
on the double dCt analysis while the statistical analyses were done on dCt values. For data represented 
as fold change, the statistical analysis was done on the Log2 Fold Change using a One Sample t-test. 
 
 
 
(v) RESULTS 
 
Identification of endothelial cell enriched genes 
To identify genes specifically induced during endothelial fate specification and differentiation, we 
utilised an embryoid body-based protocol to generate ECs from human embryonic stem cells (hESCs) 
(Figure 1A) 25. This protocol was previously shown to generate functional hESC-EC, expressing 
CD144 and CD31 and able to form tube-like structures on Matrigel 7. RNA-seq was performed (45 
million paired end reads per sample) on ribosomal RNA depleted libraries from several replicates of 
the different cell populations (Figure 1A). Principal component analysis (PCA) demonstrated tight 
clustering of replicates and segregation of populations (Figure 1B). The purified EC samples obtained 
at day 7 (d7 EC) were closer to the human saphenous vein EC (HSVEC) samples in the PCA plot, but 
clearly clustered separately suggesting the immaturity of this EC population (Figure 1B). As expected, 
hESC pluripotency markers showed a down-regulation after day 3 of differentiation while mesoderm 
markers are up-regulated. We confirmed the expression of several endothelial markers in the d7 EC 
population but also showed the expression of arterial, venous and lymphatic phenotype markers, 
suggesting endothelial heterogeneity (Supplementary Figure 1A).  As expected, we observed a high 
overlap between the genes up-regulated in d7 EC versus hESC and the genes up-regulated in HSVEC 
versus hESC (Supplementary Figure 1B), validating their endothelial identity.  
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To identify genes important for endothelial identity and function, we focused on candidates showing 
high expression in immature and mature ECs. We specifically selected 409 genes enriched in the day7 
EC population but also expressed in our HSVEC samples. Then, we took advantage of RNA-seq data 
from the ENCODE consortium to assess their expression in several EC lines from different origins but 
also in SMCs. We retrieved a list of 278 genes with high expression in ECs and lower expression in 
SMCs (Supplementary Table 2). This list contains known markers of ECs including PECAM1, CDH5, 
and ERG, and the Gene Ontology (GO) analysis revealed the enrichment of terms related to vessel 
development and angiogenesis (Supplementary Figure 1C). 
 
LINC00961 is enriched in immature and mature ECs 
Among the 278 genes enriched in immature and mature ECs, we found 6 lncRNAs: 3 antisense 
lncRNAs and 3 intergenic lncRNAs (Figure 2A and B). While antisense RNAs often regulate the 
expression of their sense genes 24, intergenic lncRNAs have function generally unrelated to their 
neighbouring protein-coding genes. From the 3 intergenic lincRNA, LINC00961 is the only one 
conserved in mouse (Figure 2C). LINC00961 is located on chromosome 9 and while LINC00961 
transcript expression was detected in the d7 EC population and HSVECs with a read profile confirming 
a two-exon gene structure, neighbouring HRCT1 expression was restricted to HSVECs (Figure 2C). 
Although LINC00961 was initially annotated as a lncRNA, the locus encodes a small ORF in the second 
exon and has been re-annotated as a protein coding gene. Interestingly, the peptide was independently 
identified based on a proteomic strategy and termed SPAAR for small regulatory polypeptide of amino 
acid response 23. To validate the RNA-seq, LINC00961 gene expression was evaluated by qRT-PCR in 
the same sample set used for RNA-seq, which demonstrated the same profile of expression 
(Supplementary Figure 2). 
 
 
LINC00961/SPAAR gene silencing affects endothelial function  
To assess the impact of silencing LINC00961 transcript on endothelial function, we depleted 
LINC00961 levels in HUVECs by 70%, utilising dsiRNAs (Figure 3A). In an in vitro 2D Matrigel 
tubule network formation assay, LINC00961 silencing resulted in attenuated branch formation (Figure 
3B & C). Calcein AM was used to confirm that the lack of branch formation following LINC00961 
depletion was not a consequence of apoptosis (Figure 3C). We confirmed that LINC00961 silencing 
did not affect cell viability using Annexin V and PI staining (Supplementary Figure 3A). We then 
replicated the network formation phenotype via a GapmeR depletion strategy (Supplementary Figure 
4). Moreover, silencing LINC00961 led to a significant reduction in cell adhesion (Figure 3D) and 
endothelial membrane barrier integrity (Figure 3E & Supplementary Figure 3B). We also observed 
a trend towards a reduction in cell proliferation (Supplementary Figure 3C), and migration 
(Supplementary Figure 3D). To investigate whether LINC00961 played a cis- regulatory role in the 
expression of the closely located gene HRCT1, we tested HRCT1 transcript levels in siRNA LINC00961 
depleted cells. qRT-PCR analysis showed that HRCT1 expression was unaltered by LINC00961 
modulation (Supplementary Figure 5A & B). Similarly, siRNA silencing of HRCT1 did not affect 
LINC00961 levels (Supplementary Figure 5C & D). 
 
 
Murine LINC00961/SPAAR locus knock out reduces adductor muscle capillary density following 
hind limb ischaemia (HLI) 
To assess the role of the LINC00961 locus in vivo, we established a knock out (KO) mouse where the 
entire locus was deleted (Figure 4A). We first confirmed the absence of the LINC00961 mouse 
transcript by qRT-PCR (Supplementary Figure 6A). We then tested the efficacy of injury-induced 
angiogenesis compared to littermate controls at two time points. After 7 days, the capillary density 
between KO and WT animals was not significantly altered in the non-ischaemic leg (p=0.2471). 
However, at 7 days after HLI LINC00961-/- mice had a lower capillary density in the ischaemic adductor 
muscle compared to controls (Figure 4B). This was therefore comparable to the in vitro tubule 
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formation data in LINC00961 depleted HUVECs. Interestingly, KO animals had a significant decrease 
in the number of α-smooth muscle actin (αSMA) positive vessels at baseline compared to WT animals 
but this difference was not evident after injury (Figure 4C). We also analysed Laser Doppler ratio, 
capillary density and αSMA positive vessels at 21 days. No significant differences at this later time 
point were observed (Supplementary Figure 6). 
 
The LINC00961 locus encodes a biologically functional RNA 
We next investigated the angiogenic effect of overexpressing either the full length LINC00961 
transcript or the SPAAR ORF sequence in HUVECs, using lentiviral vectors (LV) (Figure 5A). We 
also generated a LV-ΔΔATG961 construct (Figure 5A), corresponding to the full length transcript with 
mutations in the ORF initiation codons to block translation. qRT-PCR (Figure 5B) and western blotting 
(Figure 5C) confirmed overexpression. Overexpression of the LV-SPAAR construct significantly 
enhanced endothelial network formation, whereas LV-ΔΔATG961 produced opposite results, 
significantly inhibiting angiogenesis (Figure 5D & E).  These data showed that the production of 
SPAAR induces network formation, whereas the LINC00961 RNA alone possesses an inhibitory effect, 
independent of SPAAR micropeptide production, thus unveiling a bona fide lncRNA function for the 
LINC00961 RNA. Furthermore, we observed that LV-mediated overexpression of SPAAR, but not the 
LINC00961 transcript, reduced endothelial barrier integrity (Figure 5F). As cellular localisation of 
lncRNA transcripts is informative with regards to their associated mechanisms, we determined the 
subcellular localisation of LINC00961 using RNA-fluorescent in situ hybridisation (FISH) 
(Supplementary Figure 8A & B) and cell fractionation (Supplementary Figure 8C) and showed the 
presence of LINC00961 in both the nucleus and the cytoplasm.  
 
Identification of binding partners for LINC00961 RNA and SPAAR micropeptide  
As both LINC00961 and SPAAR are functionally relevant for ECs, we used RNA and protein pull-
downs combined with mass spectrometry to identify the protein binding partners of the lncRNA and 
SPAAR micropeptide in HUVECs (Figure 6). 147 proteins were found in the LINC00961 pulldown 
samples, which were not in the pulldown with the beads alone or the control GFP RNA (Figure 6B & 
Supplementary Tables 3 and 4). GO analysis showed enrichment of terms related to cell-cell adhesion 
and cortical actin arrangement (Figure 6D).  The top candidate was the G-actin sequestering molecule, 
thymosin beta 4-x (Tβ4) which is associated with reorganisation of the actin cytoskeleton 29 and is also 
involved in angiogenesis 30, 31. Tβ4 functions within an actin organisation pathway with other actin 
associated molecules including Cofilin-1 and Profilin-1 32. Both Profilin-1 and Cofilin-1 were enriched 
in the LINC00961 immunoprecipitation (Supplementary Table 3); suggesting LINC00961 may play a 
role in actin cytoskeleton remodelling. To confirm the interaction between LINC00961 and Tβ4, we 
carried out immunoprecipitation of endogenous Tβ4 protein in HUVECs. qRT-PCR confirmed the 
detection of LINC00961 in Tβ4 immunoprecipitation samples, thus independently validating an 
interaction of LINC00961 with Tβ4 (Supplementary Figure 10A). Immunofluorescence of Tβ4 in 
HUVECs confirmed the presence of Tβ4 in the cytoplasm in accordance with a plausible interaction 
with LINC00961 (Supplementary Figure 10B). 
 
We next identified protein binding partners for SPAAR. We found 40 proteins enriched in the HA-
SPAAR pull-down compared to the IgG pull-down controls and compared to the pull-downs in control 
cells not expressing the fusion protein (Supplementary Table 5 & 6). GO analysis of SPAAR targets 
showed enrichment of terms related to immunity (Figure 6E). SPAAR has been previously shown to 
bind the v-ATPase complex in HEK293 33. However, these proteins were not found in the SPAAR 
pull-down in HUVECs, suggesting a different function for SPAAR in ECs. The top hit for SPAAR 
interactors was SYNE1, also known as NESPRIN-1, a regulator of EC shape and migration 34. 
 
Thymosin beta 4-x depletion phenocopies LV-ΔΔATG961 overexpression 
To characterise the function of LINC00961 and Tβ4 interaction, we assessed whether they co-regulated 
each other’s expression. siRNA silencing of TMSB4X (Supplementary Figure 9A) did not alter 
LINC00961 transcript levels (Supplementary Figure 9B). Similarly, silencing LINC00961 or 
overexpressing LV-ΔΔATG961 did not change TMSB4X transcript levels (Supplementary Figure 9C 
& 9D). The known pro-angiogenic effect of Tβ4 30, 31 was confirmed in our system, with a 49±16% 
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reduction in network formation following TMSB4X depletion (Figure 7A & 7B). This reduction is 
similar to the overexpression of LINC00961 transcript without the production of SPAAR micropeptide 
(LV-ΔΔATG961), suggesting that LINC00961 lncRNA might negatively regulate Tβ4-mediated 
angiogenesis. 
 
 
 
 
(vi) DISCUSSION 
 
Using RNA-seq, we identified LINC00961 as an endothelial enriched transcript. The strong impact on 
the endothelial phenotype following LINC00961 level manipulations confirmed the relevance of our 
candidate selection using the combination of our hESC to EC RNA-seq with ENCODE RNA-seq 
datasets. This further highlights the need to investigate the role of lncRNA transcripts in endothelial 
biology.  
 
In this study, we provide in vitro and in vivo evidence that the LINC00961 locus has a function in ECs. 
Whilst siRNA KD in vitro affects many aspects of EC biology (angiogenesis, adhesion, proliferation, 
migration, and membrane integrity), we assessed the angiogenic role in a murine KO model. 
LINC00961-/- mice had fewer αSMA positive vessels at day 7 baseline, suggesting a defect in the 
development, maturity and or stability of larger vessels. After injury, KO mice has fewer capillaries at 
day 7, indicating a reduced capacity of the endothelium to undergo angiogenesis after injury. However, 
the effect of the KO was not observed by day 21 post HLI. This suggests the KO animals may have a 
slower recovery rate after injury (due to an impairment in EC function), or activate compensatory 
mechanisms to maintain vessel numbers after injury. As we have a global KO, we cannot exclude the 
contribution of LINC00961deletion in other cell types to this phenotype. To further investigate the role 
of this locus in EC behaviour, it would be worthwhile to switch to an EC-specific and conditional 
LINC00961 KO mouse model. In addition, it would be interesting to assess the effect of LINC00961 
deletion in early development of vessel establishment and further characterise the dynamics of vessel 
recovery early in the HLI model.  
 
Previous studies have outlined the role of the micropeptide SPAAR, encoded from the LINC00961 
locus, during muscle regeneration 23. In our study, we showed opposing roles of LINC00961 RNA and 
SPAAR micropeptide in angiogenesis, one being anti- and the other pro-angiogenic respectively. The 
reduction in endothelial barrier integrity with SPAAR overexpression further validates our hypothesis 
that SPAAR is pro-angiogenic. Indeed, plastic junctions are required for sprouting angiogenesis 35. It 
would therefore be interesting to test the permeability of new SPAAR induced vessels in an animal 
system using a plasma tracer. 
 
To our knowledge, this is the first reported bi-functional locus in a cardiovascular setting. In other 
biological contexts, loci producing protein or functional ncRNAs through alternative splicing have been 
described 36-38. The novelty of the LINC00961 locus is that the SPAAR micropeptide is produced from 
the functional LINC00961 RNA instead of an alternative splicing transcript without an ORF. This 
configuration implies the requirement of a regulatory mechanism to control the levels of LINC00961 
RNA and SPAAR micropeptide independently of each other. The switch between LINC00961 and 
SPAAR could be controlled at the translation level, similarly to the STORM micropeptide whose 
translation initiation is regulated by eIF4E phosphorylation 39. However, the functional activity of the 
lncRNA encoding the STORM micropeptide has never been demonstrated. Expression of the 
LINC00961 transcript is high in basal HUVECs and detectable by qRT-PCR, in contrast, we are only 
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able to see the presence of SPAAR micropeptide in LV-SPAAR conditions. This limitation is likely 
due to either very low protein levels in basal HUVECs or the detection limit of the antibody. The precise 
molecular control of LINC00961 transcript and SPAAR levels needs further dissection in light of these 
findings. 
 
We show that LINC00961 RNA binds Tβ4, a well-established actin binding protein with many 
additional functions including anti-inflammatory and anti-apoptotic properties, and a role in cell 
migration and angiogenesis 29. As TMSB4X transcript levels were not affected by LINC00961 depletion, 
we propose that LINC00961 regulates Tβ4 protein function. The enrichment of Profilin-1 and Cofilin-
1, actin monomer binding proteins, in the LINC00961 immuno-precipitation suggests a potential role 
for LINC00961 in actin recycling. Like Tβ4, Profilin-1 sequesters G-actin maintaining a large pool of 
monomeric actin. Unlike Tβ4 however, the high affinity of Profilin-1 for ATP allows it to act as a 
catalyst for the conversion of G-actin.ADP to G-actin.ATP, hence aiding the polymerisation of G-actin 
to F-actin filaments 40. In fact, Profilin-1, Tβ4, and actin have been shown to produce a complex 41. 
This, alongside the fact that Cofilin-1 and Tβ4 have been shown to co-localise in multiple cells types, 
further validates the nature of their finely balanced roles in cytoskeletal dynamics 42,43. It would be of 
interest to dissect the interactions of these three proteins with LINC00961 in future. 
 
We show that SPAAR binds to SYNE1, another actin binding protein, which suggests that the pro-
angiogenic effects of SPAAR could be mediated through SYNE1 and the actin cytoskeleton. This is in 
contrast to our proposed mechanism of action of LINC00961, which may negatively affect actin 
cytoskeleton rearrangement through interaction with Tβ4. SYNE1 is involved in the cellular 
organisation of organelles via connecting them to the actin cytoskeleton. SYNE1 is  especially 
important as a member of the linker of nucleoskeleton and cytoskeleton complex which tethers the 
nuclear lamina to the actin cytoskeleton during nuclear positioning and cell polarisation 44.  
Interestingly, SYNE1 is highly expressed in skeletal and cardiac muscle cells as it is essential in 
maintaining the characteristic peripherally located nuclei 45. Matsumoto and colleagues (2017) describe 
rapid muscle regeneration in mice lacking SPAAR; it would be interesting to ascertain if this 
phenomenon is in part mediated by an interaction, or lack thereof, between SPAAR and SYNE1. 
Furthermore, SYNE1 siRNA KD in HUVECs has been shown to reduce tubule formation in a Matrigel 
assay and decreased migration 34, 46, similar to our results with KD of the LINC00961/SPAAR locus.  
Cytoskeletal remodelling is a dynamic process which is constantly being influenced by internal and 
external signals, with many actin binding proteins having been identified 47. Here, we show that 
LINC00961 and SPAAR have independent actin binding protein partners that could influence 
downstream cytoskeletal architecture. It will be of interest to investigate if, and how, lncRNA and 
micropeptide levels can change cellular behaviour through cytoskeletal changes.  
 
 
In conclusion, our study provides important evidence for the expression and function of LINC00961 in 
ECs. Our work shows a role for the LINC00961 RNA, independent of the micropeptide SPAAR. This 
highlights the importance of a detailed bioinformatic and experimental approach to reveal the 
contribution of putative lncRNAs and their encoded proteins in cell behaviours. 
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(xi) FIGURE LEGENDS 
 
Figure 1: Identification of endothelial cell enriched genes. (A) Schematic representation of the RNA-
seq samples: day 0 H9 hESC (ESC); Day 3 mesodermal population CD326lowCD56+ (MP); Day 3 
remaining population (non-MP); Day 7 EC CD144+CD31+(EC); Day 7 remaining population (non-EC); 
Human Saphenous vein endothelial cell (HSVEC). (B) Principle component analysis (PCA) of the 
RNA-seq samples. The plot was generated on the regularized log transformed data using DESEq2. (C) 
Summary of the selection of candidates to identify genes enriched in ‘immature’ and ‘mature’ ECs (D) 
Heatmap showing the expression data (as row z-score of the Log2(FPKM+1)) during differentiation of 
the 278 EC enriched genes. (E) Heatmap showing the expression data (as row z-score of the Log2 
(FPKM+1)) of the 278 EC enriched genes in ENCODE RNA-seq samples.  
 
Figure 2: LINC00961 is enriched in immature and mature endothelial cells. (A) Heatmap of the 6 
lncRNAs identified in our EC differentiation protocol in each of the isolated cell populations. (B) 
Heatmap of these 6 lncRNAs in ENCODE RNA-seq samples including various types of EC lineages 
such as, venous, arterial and lympthatic ECs. (C) Genomic organisation of the LINC00961 gene, read 
profile from the ESC to EC RNA-seq and conservation track based on UCSC alignment and PhyloP 
score.  
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Figure 3: Functional impact of LINC00961/SPAAR depletion in endothelial cells. (A) 
Confirmation of the dsiRNA-mediated depletion of LINC00961 transcript in HUVECs by qRT-PCR 
(n=4, unpaired t-test). (B) Network formation assay in LINC00961 depleted HUVECs. Branch length 
assessed by Image J Angiogenesis plugin. (n=3, unpaired t-test). (C) Representative phase contrast and 
Calcein AM staining of network formation assay of LINC00961 depleted and control HUVECs. Phase 
Scale bar =0.5mm. Calcein AM Scale bar =0.1mm. (D) Impact of LINC00961 depletion on HUVEC 
adhesion (n=3). (E) Analysis of average barrier resistance, expressed as Rb [Ohm x cm2], across a 10 
hour time course (n=4 except for mock n=3, one-way ANOVA). For data represented as fold change, 
the statistical analysis was done on the Log2 Fold Change using a One Sample t-test. On the graphs, 
*p<0.05 **p<0.01 ***p<0.001.  
 
Figure 4:  LINC00961/SPAAR KO mice have a reduced adductor muscle capillary density 
following hind limb ischaemia at 7 days. (A) Schematic representation of the deleted region of the 
LINC00961 mouse locus using CRISPR/Cas9 technology by Taconic©. Red arrows indicate the 
position of the guide RNA strands utilised to delete the whole locus. (B) Capillary density per sample. 
Five random regions of interest  from 3 sections per sample were counted (n= 4 wild type mice/6 knock 
out mice, one-way ANOVA, ** p<0.01, ns - not significant). (C) α-smooth muscle actin (αSMA) 
positive vessel density per sample. (D) Representative adductor muscle immunofluorescent images: 
Isolectin b4 (IB4) capillary/endothelium, αSMA, and nuclear DAPI, scale bar 50µm. Zoomed panel on 
left corresponds to red box on area of WT control limb image. 
 
Figure 5: Impact of LINC00961 transcript and SPAAR micropeptide overexpression in in vitro 
angiogenic assays. (A) Schematic representation of LINC00961 LV constructs with transcript length 
in base pairs (bp) and encoded peptide length in amino acids (aa). (B) qRT-PCR validation of the LV 
constructs overexpression in HUVECs using primers targeting the ORF sequence. Unpaired t-test, 
comparison test versus LV-EMPTY (n=4). (C) Representative western blot of SPAAR micropeptide 
and β-actin in HUVECs infected with the LV constructs. (D) Network formation assay comparing 
HUVECs transfected with LV constructs.  Branch length assessed by Image J Angiogenesis plugin. 
Unpaired t-test versus LV-EMPTY, (n=3). (E) Representative Phase contrast of network formation 
assay of HUVECs transfected with LV constructs. (F) Analysis of average barrier resistance, expressed 
as Rb [Ohm x cm2], across a 10 h time course (n=4, one-way ANOVA). Scale bar =0.5mm. On the 
graphs, *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 6: LINC00961 and SPAAR both bind to actin binding proteins. 
(A) Schematic of the LINC00961 RNA and SPAAR peptide pull-down experiments in HUVECs. (B) 
List of the top 10 proteins identified in LINC00961 RNA pull-down (ranked on label free quantification 
value) (C) List of the top 10 proteins identified in HA-SPAAR peptide pull-down (ranked on label free 
quantification value)  (D) GO analysis on enriched proteins from LINC00961 immunoprecipitation. (E) 
GO analysis on enriched proteins from SPAAR immunoprecipitation. 
 
Figure 7: Thymosin beta 4-x KD in HUVECS has a similar phenotype to LV-ΔΔATG961 
overexpression on tubule formation. (A) Network formation assay in dsiRNA-mediated TMSB4X 
depleted HUVECs.  Branch length assessed by Image J Angiogenesis plugin, n=5, unpaired t-test. (B) 
Representative phase contrast and Calcein AM staining of network formation assay of depleted 
HUVECs. Phase contrast Scale bar =0.5mm. Calcein AM Scale bar = 0.1 mm. On the graphs, *p<0.05, 
**p<0.01, ***p<0.001. 
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